Key Takeaways
- One-off quarter within a growth story: Blended EBITDA margin fell to 11.1% as pigment demand and pricing collapsed globally, while a notional forex loss and a warehouse fire added noise. Management calls it a one-off inside a five-year 20% revenue CAGR.
- TiO2 plant is live, ramp-up is the next test: Phase 1 (16,500 tons) commissioned in the last week of the quarter; stabilization is expected to take 1.5–2 months, with meaningful revenue from April. Phase 2 doubling is on track for Q3 FY24.
- CDMO contract de-risks the agro pipeline: A ₹800 crore, five-year contract with a global company was signed, with ₹150–200 crore of annual revenue starting next financial year. Terms bar disclosing the molecule or volumes.
- Nano Urea is a free-market bet on policy tailwinds: The IFFCO-licensed plant targets a ₹1,000 crore annual top line, with no subsidy linkage and government pressure to displace conventional urea. Margins remain undisclosed.
- What to watch next quarter: Whether TiO2 stabilization hits its 1.5–2 month target, pigment demand begins the promised recovery from April, and Nano Urea margin clarity arrives.
TiO2: Commissioned, Stabilizing, Expanding
- Phase 1 live: The 16,500-ton plant was commissioned on 18 January 2023, just before the call. Final product had not yet been obtained; stabilization work is in progress.
- Stabilization timeline: Management expects technical challenges for 1–2 months, targeting a smooth production ramp-up from April (start of FY24). Specific quality parameters being tracked were not disclosed.
- Phase 1 revenue: At current pricing, Phase 1 should generate nearly ₹300 crore top line; if prices improve, the top line will rise. A separate estimate put FY24 contribution at ₹200 crore+.
- Phase 2 expansion: Capacity will double to 33,000 tons per annum, with a captive coal-based power plant. Commissioning is expected by end of Q3 FY24.
- Grade progression: Phase 1 will produce Anatase grade initially; after roughly one year, full capacity will convert to Rutile grade once Phase 2 capex enables Rutile production.
- Pricing outlook: TiO2 prices are expected to rise because European plants are not operating (high operating costs) and demand should improve as China and global markets open up.
- Entry barriers: Management stressed that TiO2 is not easy to manufacture and is high-capex, so small players are unlikely to enter. Ore sourcing was discussed but backward integration was not confirmed.
Ankit Patel: "It is not very easy to manufacture. That is why not every company is entering into this business and it is high CapEx nature."
Pigment Division: The Quarter's Drag
- What went wrong: Slow export demand and global price contraction hit the pigment business. Performance was further hurt by liquidation of high-cost inventory and an exceptional loss from a fire in the finished-goods warehouse.
- Fire impact: Total loss was ~₹43 crore, of which ₹39 crore was booked as a claim receivable. Only ₹4 crore (policy deductibles) hit the P&L. Management did not classify it as an exceptional item despite the quantum, considering it ordinary-course. Plant and machinery impact was minimal.
- Margin collapse: Pigment EBITDA margin fell sharply due to the combination of high-cost inventory flowing through and softening finished-product prices driven by demand contraction.
- Recovery path: Management expects demand to start picking up in the coming quarter, with normalization by end of March and improvement from April onwards. One more difficult quarter is anticipated.
- Channel dynamics: No heavy inventory buildup in the channel globally because customers bought cautiously throughout the year-long price decline while consumption continued, a positive for future demand and pricing.[18-19]
Ankit Patel: "So this has been a five years CAGR growth. So we have been consistently growing, so this is one of its quarter, you cannot have the growth continuously. There will be some ups and down in the business, so we feel this is one off quarter..."
Agrochemicals: Holding Margin, Building Pipeline
- Margin resilience: The agrochemical division maintained an EBITDA margin of nearly 19% despite adverse global macro conditions, product price reductions, and high-cost inventory carried from Q2.
- Inventory overhang fading: High-cost inventory from Q2 FY23 has been mostly consumed; a small portion will carry into Q4 FY23. Despite this, Agro EBITDA margin is expected to stay at 18–19%.
- 2,4D pricing: Average price was around ₹225 in Q3. As of the call date (23 January), prices were holding and things were returning to normal.
- Cypermethrin: Price declined ~₹50 over three months from ₹650–₹700 to ₹600–₹650; raw material prices followed downward.
- New MPP plant: The multi-purpose agrochemical plant commenced commercial production in Q3 FY23 and is stabilizing. It is expected to add meaningful contribution in FY24, with ₹300–350 crore revenue targeted at 50–60% utilization, ramping to 80–85% the following year.
- FY24 growth: Management expects 15–20% growth in the agrochemical segment for FY24.
- Brazil exposure: No issues for Meghmani; Brazil remains an important market and will continue spending on agrochemicals regardless of political changes.
CDMO Contract: A Material, Opaque Win
- The deal: A contract signed with a global company, valued at approximately ₹800 crore over five years, extendable further. The name of the product and quantum cannot be disclosed per contract terms.
- Revenue contribution: Execution starts as per the financial year; approximately ₹150–200 crore can come from that contract itself annually.
- Strategic significance: The contract provides multi-year revenue visibility and diversifies the agrochemical segment beyond conventional crop-protection products, though the lack of disclosed molecule or pricing terms limits external assessment.
Nano Urea: Policy Tailwind, Margin Unknown
- The agreement: Meghmani Crop Nutrition Limited (MCNL), a wholly owned subsidiary, signed an agreement with IFFCO to manufacture Nano Urea (liquid) under IFFCO's patented technology. Meghmani is among the first private-sector companies to get this agreement.
- Product differentiation: Half a litre of Nano Urea is equivalent to a 45 kg bag of conventional urea, delivering the same or better results on one acre at roughly 1% of the volume.
- Market positioning: Pricing is purely free market with no subsidy linkage; the government has no control on pricing. There is significant government pressure to convert conventional urea to Nano Urea to reduce the ₹2,50,000 crore subsidy burden.
- Revenue ambition: MCNL aims to achieve a top line of nearly ₹1,000 crore on a full-year annual basis. The plant will commence commercial production in Q4 FY24.
- Margin unknown: Management declined to disclose margin expectations, stating more clarity will come after receiving technical details from IFFCO, probably next quarter. Royalty terms to IFFCO are confidential per the agreement.
- Synergy: The customer base, dealer and distributor network remains the same as existing agrochemical operations, and there is always demand for a better product.
- Expansion optionality: Land bank is available for further capacity expansion beyond the first phase if growth warrants.
Ankit Patel: "It is purely free market. There is no subsidy linkage to this product, so the government has no control on pricing. So anyone can sell at any price for this product."
Forex, Fire & Accounting Noise
- Forex loss mechanics: Q3 saw a net ₹18 crore loss on foreign currency borrowings because the Euro appreciated more than 12% (79 to 88) while the dollar moved only 3–4%. The majority of the ₹38 crore MTM loss is unrealized, arising from restating long-term borrowings at the quarter-end closing rate.
- Offsetting gain: Other income included a ₹19 crore forex gain on receivables. Both entries are non-cash, purely accounting-driven. The company remains naturally hedged 60–65% and recorded a 9M currency gain of ₹73 crore on receivables.
- Policy stance: Management never speculates on foreign currency; this was the first quarter with such high volatility, which was beyond anyone's control. The trade-off: Euro borrowing costs ~2–2.5% vs dollar ~6%, so the lower interest cost is weighed against periodic currency swings.
- Fire loss treatment: The ~₹43 crore fire loss was largely covered by insurance (₹39 crore claim receivable). Only ₹4 crore in deductibles was recognized as a loss. Management did not classify it as exceptional, considering it ordinary-course despite the quantum.
- Insurance timeline: The claim is already under assessment and expected to be received in one quarter.
Gurjant Singh Chahal: "We are very much cautious about it, but we have to take a trade off... Dollar also moved from 75 to 82 during the year... while Euro had moved only 84 to 88 relatively. But if you see the borrowing cost in dollar today, it is almost 6%, while euro it is around 2%-2.5%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| TiO2 Phase 1 stabilization | Plant commissioned; stabilization in progress | 1.5–2 months (by ~Mar 2023) |
| TiO2 Phase 1 revenue | ~₹300 crore top line at current pricing | FY24 |
| TiO2 Phase 2 commissioning | Capacity doubled to 33,000 tons + captive power plant | End of Q3 FY24 |
| Pigment demand recovery | Normalization expected | By end of March; improvement from April |
| Overall EBITDA margin | Recovery to 14% | Going forward (no date) |
| Agrochemical segment growth | 15–20% growth | FY24 |
| New agrochemical MPP plant revenue | ₹300–350 crore (full-year potential ₹650 crore) | FY24 |
| CDMO contract revenue | ₹150–200 crore annually from the contract | Starting FY24 |
| Nano Urea commercial production | Plant commencement | Q4 FY24 |
| MCNL (Nano Urea) top line | ~₹1,000 crore on full-year annual basis | Full-year run-rate (no date) |
| Insurance claim receipt | Fire claim under assessment | Within one quarter |
| Debt repayment (scheduled) | ~₹98 crore next year, ~₹120 crore thereafter | FY24 and beyond |
| Working capital range | 90–100 days | Ongoing |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue (9M FY23) | Nearly ₹2,000 cr, +18.5% YoY |
| Net profit (9M FY23) | ₹205 cr |
| EBITDA margin (9M FY23) | 14.1% |
| EBITDA margin (Q3 FY23) | 11.1% |
| Agrochemical division EBITDA margin | Nearly 19% |
| ROCE | 15% as on 31st December 2022 |
| ROE | 18% as on 31st December 2022 |
| Cash and cash equivalents | ₹77 cr as on 31st December |
| Debt to equity ratio | 0.43 as on 31st December |
| Gross debt: short-term | ~₹260 cr as on 31st December |
| Gross debt: long-term | ~₹430 cr as on 31st December |
| Net foreign currency loss (Q3 FY23) | ₹19 cr |
| Net foreign currency gain (9M FY23) | ₹35 cr |
| Borrowing cost net of forex impact (Q3 FY23) | Nearly ₹5.5 cr |
| Borrowing cost net of forex impact (9M FY23) | ₹11.7 cr |
| Agrochemical revenue contribution | ~75% of overall revenue |
| Pigment revenue contribution | ~25% of overall revenue |
| Export revenue contribution | ~85% of overall revenue |
| Foreign currency exposure hedged | 60% to 65% via natural hedge |
| 2,4D average price (Q3 FY23) | ~₹225 |
| Cypermethrin price | ₹600–₹650, down from ₹650–₹700 three months ago |
| Agrochemical capacity utilization (ex-new plant) | >75%, nearly 80% |
| Pigment capacity utilization | ~55% to 60% |
| Titanium dioxide Phase 1 capacity | 16,500 tons, commissioned 18th January 2023 |
| Titanium dioxide Phase 1 expected top line (at current prices) | Nearly ₹300 cr |
| Titanium dioxide Phase 2 completion target | Q3 FY24, doubling capacity to 33,000 tons per annum |
| New agrochemical MPP plant full-year revenue potential | ~₹650 cr |
| New agrochemical MPP plant expected FY24 revenue | ₹300–350 cr |
| CDMO contract value | ₹800 cr over five years, extendable |
| Nano urea plant CapEx | Nearly ₹150 cr for capacity of 5 cr bottles per year |
| Nano urea plant commercial production start | Q4 FY24 |
| MCNL targeted top line (full-year annual basis) | Nearly ₹1,000 cr |
| Nano urea project working capital requirement | ~₹200 cr on full-year basis |
| Fire loss: total | ~₹43 cr; ₹39 cr recognized as claim receivable, ₹4 cr accounted as loss |
| Annual debt repayment | ~₹98 cr next year, then ~₹120 cr as per schedule |
| Working capital days | 90–100 days |
| Five-year revenue CAGR (FY18–FY22) | ~20% |
| Five-year EBITDA CAGR (FY18–FY22) | >20%, nearly 22%–23% |
| Five-year PAT CAGR (FY18–FY22) | ~40% |